10-K: Grace Therapeutics Reports Positive Phase 3 Results for Lead Drug GTx-104, Eyes FDA Submission Amidst Continued Operating Losses

Grace Therapeutics, Inc. announced positive Phase 3 clinical trial results for its lead drug candidate, GTx-104, and plans for an FDA New Drug Application submission in the first half of calendar year 2025, despite reporting continued operating losses and a need for additional capital.

Summary

• Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies.
• The company's lead drug candidate, GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), successfully met its primary endpoint in the Phase 3 STRIVE-ON trial, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• GTx-104 demonstrated significantly lower interand intra-subject pharmacokinetic variability and 100% bioavailability compared to approximately 7% for oral nimodipine.
• The company plans to submit a New Drug Application (NDA) for GTx-104 to the FDA in the second quarter of 2025, based on positive feedback from a Type C meeting with the FDA.
• Grace Therapeutics reported a net loss of $9.568 million for the fiscal year ended March 31, 2025, an improvement from a net loss of $12.853 million in the prior year.
• Research and development expenses increased by $4.828 million to $9.511 million, primarily due to increased activities for the GTx-104 pivotal Phase 3 trial.
• The company's cash and cash equivalents stood at $22.133 million as of March 31, 2025, down from $23.005 million at March 31, 2024.
• A private placement in February 2025 generated net proceeds of $13.705 million, which is expected to sustain planned operations into the third calendar quarter of 2026.
• The company has de-prioritized the development of its other drug candidates, GTx-102 (for Ataxia Telangiectasia) and GTx-101 (for Postherpetic Neuralgia), and is exploring out-licensing or sale opportunities for them.
• All three drug candidates (GTx-104, GTx-102, GTx-101) have received Orphan Drug Designation (ODD) from the FDA, which provides potential marketing exclusivity and financial benefits like tax credits and NDA fee waivers.
• The company underwent a corporate redomiciliation from Canada to Delaware, United States, effective October 7, 2024, and changed its name to Grace Therapeutics, Inc. on October 28, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful Phase 3 trial for the lead candidate GTx-104 and a clear path to NDA submission, which is a significant de-risking event. The recent capital raise also provides a runway. However, the company still faces substantial financial challenges, including continued operating losses, a need for significant future funding for commercialization, and the de-prioritization of other pipeline assets, which temper overall optimism.

Positives

• GTx-104's Phase 3 STRIVE-ON trial met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• GTx-104 showed a 29% relative increase in patients with favorable outcomes at 90 days follow-up on the modified Rankin scale compared to oral nimodipine.
• Patients receiving GTx-104 experienced fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days.
• GTx-104 exhibited 100% bioavailability and significantly lower pharmacokinetic variability compared to oral nimodipine's approximately 7% bioavailability.
• FDA feedback from a Type C meeting suggests that the current data and regulatory packages for GTx-104 are sufficient for NDA submission.
• The company secured $13.705 million in net proceeds from a private placement in February 2025, extending its operating runway into the third calendar quarter of 2026.
• Net loss decreased to $9.568 million in fiscal year 2025 from $12.853 million in fiscal year 2024.
• All three pipeline drug candidates (GTx-104, GTx-102, GTx-101) have received Orphan Drug Designation (ODD), offering potential market exclusivity and financial incentives.
• The company has a robust intellectual property portfolio with over 40 granted and pending patents globally, including 8 U.S. issued patents.

Negatives

• The company continues to incur significant operating losses and negative cash flows from operations since its inception, with a net loss of $9.568 million for the fiscal year ended March 31, 2025.
• Research and development expenses increased significantly by $4.828 million, indicating higher cash burn for clinical trials.
• The company has no history of commercializing drugs, which presents a challenge in evaluating future viability and revenue generation.
• Additional capital will be required to fund daily operating needs beyond the third calendar quarter of 2026, and especially for the commercial launch of GTx-104.
• The development of GTx-102 and GTx-101 has been de-prioritized, with their future contingent on securing additional funding or strategic partnerships, indicating uncertainty for these assets.
• The company is heavily dependent on the success of its single lead drug candidate, GTx-104, concentrating development risk.

Risks

• The company may not achieve publicly announced milestones on time, or at all, which could adversely affect business and stock price.
• Heavy dependence on the success of GTx-104 means any delay or setback in its development could substantially harm the business.
• Inability to maximize value from de-prioritized drug candidates (GTx-102 and GTx-101) through development, out-licensing, or sale.
• Need for additional funding to maintain operations and advance GTx-104 commercialization; inability to raise capital could negatively impact financial condition and business strategy.
• Lack of history in commercializing drugs makes it difficult to assess future viability.
• Disruptions at regulatory agencies (FDA, SEC) due to U.S. presidential administration changes, funding shortages, or global health concerns could delay product development and approval.
• Uncertainty regarding the FDA's acceptance of the 505(b)(2) regulatory pathway for drug candidates, potentially leading to longer, costlier, and more complex approval processes.
• Clinical development is lengthy, expensive, and unpredictable; earlier study results may not predict future trial outcomes, and failure can occur at any stage.
• Potential for undesirable side effects from product candidates, which could prevent regulatory approval or market acceptance.
• Risk of third-party intellectual property infringement claims, especially due to reliance on the 505(b)(2) pathway, leading to costly litigation and potential delays.
• Market opportunities for GTx-104 may be smaller than estimated, adversely affecting results of operations.
• Uncertainty relating to healthcare reform measures and reimbursement policies, which could hinder or prevent commercial success.
• Inability to differentiate drug candidates from branded reference drugs or existing generic therapies could adversely affect commercialization.
• Significant competition from other biotechnology and pharmaceutical companies with greater resources.
• Reliance on third parties for pre-clinical studies, clinical trials, and manufacturing, which introduces risks if these parties fail to meet duties or deadlines.
• Potential for classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for prior years, potentially tainting common shares owned by U.S. Holders.
• Limitations on the ability to use net operating loss carryforwards (NOLs) to offset future taxable income due to ownership changes or expiration.
• Volatility in the price of common stock due to various factors, including clinical trial results, regulatory approvals, and market conditions.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or drug candidates.
• Risks related to the personal data collected, processed, and shared, including compliance with evolving data privacy laws (e.g., GDPR, CCPA) and potential for significant penalties for non-compliance.
• Reliance on information technology and third-party software, making the company vulnerable to cybersecurity incidents, which could disrupt operations and lead to data loss or disclosure.

Future Outlook

Grace Therapeutics plans to submit an NDA for GTx-104 to the FDA in the second quarter of 2025, with the potential to transform the standard of care for aSAH patients if approved. The company expects to require additional capital to support the commercial launch of GTx-104 and further development of its de-prioritized drug candidates, GTx-102 and GTx-101, which may involve strategic partnerships, licensing, or sale. The company anticipates continued significant expenses and operating losses for the foreseeable future as it advances its drug candidates and builds commercial capabilities.

Management Comments

• "We believe these data validate the GTx-104 value proposition and we plan to submit an NDA to the FDA in the first half of calendar year 2025."
• "If approved, GTx-104 has the potential to address significant challenges with oral nimodipine administration and may transform the standard of care for patients with aSAH."
• "We plan to collaborate with our scientific advisory board and FDA (via Type C meeting) on the design of a potential pivotal efficacy and safety trial and will determine the next steps after that time [for GTx-102]."
• "Further clinical development work will be contingent on additional funding for GTx-102 or the signing of a strategic partnership. It is also possible that we may license or sell our GTx-102 drug candidate."
• "The further development of GTx-101 has been deprioritized in favor of our focus on development of GTx-104. Pending additional funding for GTx-101 or the signing of a strategic partnership, we plan to follow this successful PK trial with the next step of the clinical development plan including a multiple ascending dose trial."
• "We believe our existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of these consolidated financial statements included in the Company’s Annual Report on Form 10-K."
• "We will require additional capital to fund our daily operating needs beyond that time."
• "We do not expect to generate revenue from product sales unless and until we successfully complete drug development and obtain regulatory approval, which is subject to significant uncertainty."

Industry Context

Grace Therapeutics operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting rare and orphan diseases. The company's strategy of repurposing existing pharmaceutical compounds via the 505(b)(2) regulatory pathway aims to reduce development time and cost compared to novel drug development. The focus on orphan diseases aligns with industry trends seeking benefits like market exclusivity and tax credits. The market for aSAH, A-T, and PHN represents significant unmet medical needs, positioning Grace Therapeutics to potentially capture market share if its differentiated formulations gain approval and market acceptance. The industry faces ongoing scrutiny regarding drug pricing and reimbursement policies, which could impact future commercial success.

Comparison to Industry Standards

• **GTx-104 (aSAH):** The Phase 3 STRIVE-ON trial's positive outcome (19% reduction in hypotension, 29% relative increase in favorable outcomes) suggests a clinically meaningful improvement over the current standard of care, oral nimodipine (e.g., NYMALIZE by Azurity Pharmaceuticals). The 100% bioavailability of GTx-104 compared to ~7% for oral nimodipine represents a significant pharmacokinetic advantage, addressing known issues with oral administration like variable absorption and food effects. This could lead to more consistent drug levels and better blood pressure management, a key unmet need in aSAH patients. While direct competitor clinical trial data for IV nimodipine alternatives are not detailed, the reported benefits position GTx-104 favorably against the existing oral standard.
• **GTx-102 (A-T):** As the first potential therapy for Ataxia Telangiectasia, GTx-102 addresses a significant unmet medical need where no FDA-approved therapies currently exist. The licensed data from the Zannolli trial, showing a median 28-31% decrease in ataxia symptoms (ICARS total score) with oral betamethasone, provides a strong clinical basis. Achieving similar blood levels at 1/70th the volume of an oral solution offers a substantial convenience advantage for pediatric A-T patients who often have swallowing difficulties, potentially improving patient compliance compared to traditional oral solutions of betamethasone (which is currently only available as injectable or topical cream in the US).
• **GTx-101 (PHN):** GTx-101 aims to improve upon existing PHN treatments like oral gabapentin and lidocaine patches (e.g., Lidoderm). The reported biphasic delivery mechanism for rapid onset and continuous pain relief for up to eight hours, along with touch-free, non-greasy application and no skin sensitivity in Phase 1, suggests potential advantages over lidocaine patches which are often cited for insufficient pain relief (40% of patients), difficulty of use, falling off, unsightly appearance, and 12-hour on/off restrictions. While specific comparative efficacy data against gabapentin or lidocaine patches are not provided in this document, the formulation's characteristics address known patient complaints with current therapies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in the opinion of management, are likely to have a material adverse effect on its business.

Related Party Transactions

• In the February 2025 private placement, related parties (Shore Pharma LLC, ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC) purchased securities, contributing $5.694 million in proceeds.
• In the September 2023 private placement, related parties (Shore Pharma LLC and SS Pharma LLC) participated, contributing $2.500 million in proceeds.
• As of March 31, 2025, the balance of derivative warrant liabilities from related parties was $952,000, down from $1.453 million as of March 31, 2024.

Stakeholder Impact

• **Shareholders:** Positive Phase 3 results for GTx-104 and plans for NDA submission could increase shareholder confidence and potentially lead to future share price appreciation if approved and commercialized. However, continued operating losses and the need for future capital raises pose dilution risks.
• **Employees:** The strategic realignment in May 2023 involved a substantial workforce reduction, impacting former employees. The company's focus on building a high-performing organization and retaining key executives is crucial for current employees.
• **Customers (Future Patients/Healthcare Providers):** Successful development and commercialization of GTx-104 could provide a significantly improved treatment option for aSAH patients, offering better outcomes and ease of administration. Future products like GTx-102 and GTx-101 could address unmet needs in A-T and PHN.
• **Suppliers/CMOs/CROs:** The company's reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) means these partners are critical to its operational success and will continue to be key stakeholders.
• **Creditors:** The company's ongoing operating losses and need for future financing indicate a reliance on external capital, which could affect its credit profile. The recent private placement provides some liquidity, but long-term financial stability depends on commercial success.

Next Steps

• Submit a New Drug Application (NDA) for GTx-104 to the FDA in the second quarter of 2025.
• Continue pre-commercial planning, commercial team buildout, and product launch preparations for GTx-104 if approved.
• Collaborate with scientific advisory board and FDA (via Type C meeting) on the design of a potential pivotal efficacy and safety trial for GTx-102.
• Determine next steps for GTx-102 development, contingent on additional funding or strategic partnerships.
• Seek to maximize the value of de-prioritized drug candidates GTx-102 and GTx-101, including through potential development, out-licensing, or sale.
• Conduct a multiple ascending dose trial for GTx-101, pending additional funding or strategic partnership.
• Raise additional capital prior to the third calendar quarter of 2026 to maintain adequate liquidity and fund commercial launch of GTx-104.
• Evaluate seeking pediatric exclusivity for approved products as appropriate.

Key Dates

Recommendation

Keywords

Grace Therapeutics, GTx-104, Nimodipine, aSAH, Aneurysmal Subarachnoid Hemorrhage, Orphan Drug Designation, FDA Approval, 505(b)(2) Pathway, Clinical Trials, Phase 3 STRIVE-ON, Biopharmaceutical, Rare Diseases, Drug Delivery Technologies, SEC Filing, 10-K, Financial Results, Capital Raise, GTx-102, Ataxia Telangiectasia, GTx-101, Postherpetic Neuralgia, Intellectual Property, Corporate Governance, Nasdaq